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    Caucasians (CEU)  
from NCBI 
database 
HH/CY, HH/YY 
 and HD/CY individuals 
(n.75) 
HD/CC, DD/CC 
individuals (n.191)     
    
 c.-582 A>G / c.-1010C>T  Frequency (%) Frequency (%) [n] p* Frequency (%) [n] p* 
Allele A/C 83.6 78.7 [118] 
0.18572 
68.8 [263] 
0.00006 
G/T 16.4 21.3 [32] 31.2 [119] 
Total 100.0 100.0 [150] 100.0 [382] 
Genotype AA/CC 69.0 62.7 [47] 
0.01464 
47.1 [90] 
<0.00001   AG/CT 29.3 32.0 [24] 43.5 [83] 
  GG/TT 1.7 5.3 [4] 9.4 [18] 
  Total 100.0 100.0 [75]   100.0 [191]   
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Hepcidin is a 25 amino-acid peptide hormone known as the main regulator of iron 
homeostasis. It is able to decrease the absorption of dietary iron in the duodenum and the 
release of recycled iron from macrophages as well as the export of the stored iron from 
hepatocytes1.  
Hepcidin deficiency causes iron overload and, in contrast, its overproduction is associated with 
iron deficiency/anemia2.  
Several mutations located in the hepcidin gene (HAMP)  have already been associated to the 
development of iron overload or hereditary hemochromatosis (HH). Additionally, some  HAMP 
promoter variants were described, however their functional consequences remain unclear.  
One of them is the polymorphism c.-582 A>G that was recently described as worsening iron 
overload phenotype in beta-thalassemia major patients3 but that has no effect on the iron 
status in the healthy population4. Functional assays performed have revealed that hepcidin 
expression was slightly reduced under the promoter variant G when transactivated by the 
upstream stimulatory factors 1 and 2 (USF1/USF2) in HepG2 cells5.  
The aims of this study were to determine: i) the frequency of the c.-582 A>G HAMP 
polymorphism in patients presenting iron overload and the common HFE mutations (H63D 
and/or C282Y); ii) if it is a modulator of iron overload in these patients and, iii) which are the 
upstream stimuli that are impaired by the polymorphism presence by performing functional in 
vitro studies in HAMP promoter. 
→ 266 individuals with ferritin levels higher than 400ng/mL were screened for the 2.7-kb HAMP 
promoter variants 
(i) 191 individuals homozygous or heterozygous for the H63D allele 
(ii) 75 individuals carrying one or more C282Y alleles  (HH/CY, HH/YY or HD/CY)  
 
→ The 1.5-kb HAMP promoter sequence was cloned into the pGL2-enhancer vector and site-
directed mutagenesis  performed to obtain the polymorphic construct . 
 
→ Huh-7 hepatoma cells were seeded in 35-mm plates, and the pGL2-enhancer constructions 
co-transfected along with pGL4.70 vector. Three hours post-transfection cells were submitted to 
different stimuli: (i) 20µM holo-transferrin, (ii) 4-6µM ferric citrate, (iii) 20ng/mL interleukin-6, 
(iv) 200µM cobalt chloride and (v) GDF15 at physiological and pathological concentrations (500 
and 150000pg/mL, respectively). Finally cells were harvested and luminescence assays 
performed. 
 
 
HAMP promoter variants screening 
c.-582 A>G c.-1010 C>T 
→ The G/T haplotype frequency (31.2%) observed in the group of individuals presenting one or two H63D 
alleles (HD/CC and DD/CC individuals) is much higher than the one observed in the CEU population (16.4%),  
while no significant differences are observed in the individuals carrying at least one C282Y allele (21.3%) 
 
→ The genotype distribution in the sample of individuals carrying at least one C282Y mutation is significantly 
different (p=0.01464) from the one obtained for the control population, since the frequency of GG/TT 
genotype is 3.1-fold higher in this study group 
 
→ Also, we observe an highly significant difference (p<0,00001) between the genotype distribution in HD/CC, 
DD/CC individuals when compared to the control population. Genotype appear to be biased by a high 
frequency of GG/TT and AG/CT individuals (9.4 and 43.5%, respectively) and a lower frequency in AA/CC 
individuals (47.1%) 
* p-values were obtained by the Chi-square test 
Luminescence assays 
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Holo-transferrin and ferric citrate 
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Interleukin-6 and cobalt chloride  
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Growth differentiation factor-15 
→ Two polymorphisms were found in the proximal region of the HAMP promoter, the c.-582 A>G and              
c.-1010 C>T 
 
→ These polymorphisms appear to be in linkage desequilibrium in our sample  
→ Both holo-transferrin and ferric citrate stimuli 
partially inhibit the 1.5kb-HAMP promoter activity 
 
→ No differences in the luciferase activity were 
observed in the polymorphic promoter when 
compared to the normal   
→ IL-6 is able to increase the promoter activity, while 
cobalt chloride, mimicking hypoxia, represses it. 
 
→ Also, no differences in the luciferase activity were 
observed in the polymorphic promoter when 
compared to the normal   
→ GDF-15 stimulus seems not to affect the HAMP 
promoter activity neither at physiological nor 
pathological (beta-thalassemia) concentrations 
 
→ Again, no differences in the luciferase activity 
were observed in the polymorphic promoter when 
compared to the normal   
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In our study sample, the c.-582 A>G HAMP promoter polymorphism seems to be in linkage 
disequilibrium with the c.-1010 C>T HAMP polymorphism.   
In individuals that present ferritin levels higher than 400ng/mL along with H63D or C282Y 
mutations in HFE gene, the AG/CT and GG/TT genotypes are significantly more frequent than 
in the control caucasian population (NCBI database). This is also revealed by the significant 
differences obtained for the allele frequencies in the group presenting one or two H63D alleles 
(HD/CC and DD/CC individuals). However, this is not observed in the group presenting at least 
one C282Y allele (HH/CY, HH/YY and HD/CY individuals). 
In silico studies show that both polymorphisms can disrupt highly predictable transcription 
factor binding sites, such as USF2 and TATA.  We tried to find which stimuli are impaired by 
these variants, however after performing luminescence assays we have found that neither 
holo-Tf, ferric citrate, IL-6, hypoxia nor GDF-15 seem to be the stimuli that become unable to 
trigger the HAMP promoter activity. 
In conclusion,  c.-582 A>G and c.-1010 C>T polymorphisms seem to be a risk factor to iron 
overload development in individuals that by their H63D or C282Y background are already 
prone to develop this phenotype. 
